The routinely applied therapeutic/prognostic decisional algorithm Barcelona clinic liver cancer (BCLC), traditionally based on tumor burden, liver function (Child-Pugh, model of end-stage liver disease (MELD), and albumin-bilirubin “ALBI” score), and patient’s physical status (ECOG), in its most recent version introduced for the first time AFP as a criterium for liver transplant evaluation and to assess the eligibility to systemic treatment with ramucirumab [8]. Here, ALB is linked to neoplasm.